Full name
The OCEAN Study: A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy
NCT Number
NCT05263934
Geography
US
Non-US
Locations
Argentina, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Portugal, South Korea, Spain, Sweden, United Kingdom, United States
Primary Endpoints
Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [≤] 4 milligram [mg] per day). Up to Week 52
Order
1
Disease
Version
Phase
3
Status
Recruiting